Stage 4 non-small cell lung cancer is traditionally considered advanced and incurable in the traditional sense, as the cancer has spread beyond the chest to distant organs or tissues. However, modern medical advancements—including targeted tyrosine kinase inhibitors, precision immunotherapy regimens, and combination treatments—have dramatically transformed prognoses, turning stage 4 NSCLC into a manageable chronic condition for many patients and enabling long-term survival.